Best Agrolife Limited has informed the Exchange about Transcript for earning call held on 09 February , 2026
BESTAGRO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Best Agrolife reported Q3 FY26 revenue of Rs. 202.9 crore, down 26% YoY from Rs. 274.1 crore, mainly due to unseasonal October rainfall (49% above long-period average) and weak pest pressure that reduced crop-protection demand. Gross margin held at 32% with EBITDA at Rs. 3.8 crore (vs Rs. 5.8 crore loss YoY), though the company still posted a Rs. 12.7 crore net loss. Nine-month revenue fell to Rs. 1,101 crore (from Rs. 1,540 crore) with EBITDA margin at 11.5% and PAT of Rs. 46.1 crore. Management said new patented products BestMan and Fetagen have crossed 4 lakh treated acres each, and the patented portfolio declined only 5% versus a 48% drop in non-patent/generic sales. Full-year FY26 revenue is guided at Rs. 1,300-1,400 crore, FY27 at Rs. 1,500-1,600 crore, with long-term EBITDA margin target of 16-17% rising to 20%.
Mixed near-term but constructive longer-term: weak Q3 numbers and the open warrant conversion (exercise price far above current share price) keep short-term pressure on the stock, but guidance for a return to Rs. 1,700-1,800 crore revenue and 16-20% EBITDA margins within 2 years, along with new patented product traction, supports a gradual recovery thesis for patient shareholders.